Form 4: CEO Sells SRRK Shares for Tax Obligation

Scholar Rock CEO David Hallal sold 57,450 shares of common stock at $42.7 per share to cover tax withholding obligations related to PSU vesting.

Summary

• CEO David Hallal sold 57,450 shares of Scholar Rock Holding Corp (SRRK) common stock on January 13, 2026.
• The shares were sold at a price of $42.7 per share.
• This transaction was a non-discretionary 'sell to cover' to satisfy tax withholding obligations arising from the vesting of performance-and time-based restricted stock units (PSUs).
• Following the transaction, Mr. Hallal directly beneficially owns 1,541,645 securities, which include 166,645 common stock, 250,000 restricted stock units, and 1,125,000 PSUs.
• He also indirectly owns 205,000 shares through the Hallal Family Irrevocable Trust 2012.
• The PSUs were granted on April 27, 2025, with 125,000 shares vesting on January 12, 2026, and an additional 125,000 shares scheduled to vest on April 27, 2027.
• Remaining PSUs are set to vest in tranches based on the company's common stock achieving certain price targets and time-based vesting over four years, contingent on Mr. Hallal's continued service.
• Any PSUs that have not vested by April 27, 2029, will be forfeited without consideration.

Sentiment

Score: 6

Explanation: The transaction is a routine 'sell to cover' for tax purposes, not a discretionary sale, which mitigates negative sentiment. The vesting of PSUs is generally positive as it indicates performance milestones were met. However, any sale, even for tax, can be perceived with slight caution by some investors.

Positives

• The vesting of performance-and time-based restricted stock units indicates the achievement of certain company or individual performance milestones.
• The sale was explicitly stated as non-discretionary and solely for tax purposes, suggesting no negative sentiment from the CEO regarding the company's future prospects.

Negatives

• A sale of 57,450 shares, even for tax purposes, could be perceived with slight caution by some investors, despite the stated reason.

Risks

• Future vesting of a significant portion of PSUs is contingent on the Reporting Person's continued service relationship with the Issuer and the company's common stock achieving specific price targets, introducing performance and retention risks.
• Any PSUs that have not vested by April 27, 2029, will be forfeited, representing a potential loss of future equity for the CEO.

Future Outlook

The future vesting of a significant portion of the CEO's PSUs is tied to the company's common stock achieving certain price targets and his continued service, indicating a long-term incentive structure aligned with future stock performance and executive retention.

Management Comments

• "The sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a 'sell to cover' transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person."
• "The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."

Industry Context

This is a standard insider transaction (Form 4) related to equity compensation. In the biotechnology sector, executive compensation often includes substantial equity components like PSUs, aligning management incentives with long-term shareholder value. 'Sell to cover' transactions are common for tax obligations upon vesting of such awards.

Comparison to Industry Standards

• "Sell to cover" transactions are a common and accepted practice for executives in publicly traded companies across various industries, including biotechnology, to manage tax liabilities arising from equity compensation vesting.
• The structure of PSUs, combining performance-based and time-based vesting, is a standard approach in executive compensation packages, similar to those seen at peer biotech companies like Biogen or Vertex Pharmaceuticals, aiming to incentivize long-term performance and retention.
• The reported sale price of $42.7 per share for SRRK stock can be compared to recent trading ranges of other clinical-stage biotech companies with similar market capitalizations and pipeline stages to assess relative valuation, though this filing does not provide enough data for a direct comparison.

Related Party Transactions

• Indirect beneficial ownership of 205,000 shares through the Hallal Family Irrevocable Trust 2012, where the Reporting Person's spouse serves as a trustee. The Reporting Person disclaims beneficial ownership except for pecuniary interest.

Stakeholder Impact

• Shareholders: The sale is non-discretionary for tax purposes, so it should not signal a lack of confidence from the CEO. The vesting of PSUs indicates the CEO's incentives are aligned with long-term shareholder value.
• Employees: The CEO's continued equity compensation structure, tied to performance and time, reinforces a commitment to long-term company success.

Next Steps

• Monitoring the vesting of the remaining 125,000 PSUs scheduled for April 27, 2027.
• Observing the company's stock price performance relative to the targets for the remaining performance-based PSUs.
• Tracking the CEO's continued service relationship with the Issuer until April 27, 2029, for the full vesting of PSUs.

Key Dates

Recommendation

This Form 4 filing details a non-discretionary "sell to cover" transaction by the CEO to satisfy tax obligations upon the vesting of restricted stock units. Such transactions are routine and do not typically signal a change in management's outlook or the company's fundamentals. The vesting itself indicates the achievement of prior performance milestones. Therefore, this specific filing does not provide new information that would warrant a change in investment recommendation; a "hold" stance is appropriate, maintaining existing positions based on broader company analysis rather than this specific insider transaction.

Keywords

Scholar Rock Holding Corp, SRRK, David Hallal, Form 4, Insider Transaction, Stock Sale, Restricted Stock Units, PSUs, Equity Compensation, Tax Withholding, CEO, Biotechnology